Dr. Rahul Kushwah reports

QSCREEN AI APPOINTS FORMER PENTAGON JOINT ARTIFICIAL INTELLIGENCE CENTER DIRECTOR LT. GEN. MICHAEL S. GROEN (RET.) TO ADVISORY BOARD FOLLOWING LIVE PLATFORM DEMONSTRATION

QScreen AI Inc. has appointed Lieutenant General Michael S. Groen (retired) to its advisory board. Lt. Gen. Groen is the former director of the Joint Artificial Intelligence Center (JAIC) at the U.S. Department of Defense. Lt. Gen. Groen reviewed the QAI platform during a live demonstration in Toronto prior to confirming his appointment to the advisory board.

Who Lt. Gen. Groen is

Lt. Gen. Groen served 36 years in the United States Marine Corps. His final posting was director of the Joint Artificial Intelligence Center at the Pentagon, a Senate-confirmed position in which he led the Department of Defense's effort to develop, deploy and scale artificial intelligence across the army, navy, air force, Marines, Space Force and the combatant commands. During his tenure, he led the Department of Defense's strategy for evaluating, deploying and scaling artificial intelligence technologies across military operations.

Platform validation and institutional relevance

Lt. Gen. Groen reviewed the QAI platform through a live demonstration in Toronto on May 11, 2026, prior to joining the advisory board. QScreen believes his experience across defence, AI deployment and government operations will support commercialization efforts in correctional health, national defence and federal security markets where operational reliability and institutional credibility are critical.

QAI platform is a proprietary physiological AI screening platform designed to identify probable impairment patterns and substance classes in real time from a standard camera, without a blood test, breathalyzer or urine sample. Using existing hardware, the platform analyzes 34 physiological signals across camera and voice modalities and administers 13 validated clinical instruments, including assessments related to intoxication and withdrawal-associated conditions. The platform is designed to analyze physiological signals associated with multiple substance classes, including alcohol, opioids, benzodiazepines, stimulants and cannabis with an additional ability to identify opioid and benzodiazepine withdrawal independently from intoxication-related indicators.

Commercial and institutional market opportunities

Lt. Gen. Groen and Global Frontier Advisors are supporting QScreen's commercialization efforts across correctional health, defence, transportation and federal security environments where rapid physiological screening, documentation and operational readiness are increasingly becoming institutional priorities.

Lt. Gen. Groen commented: "I have spent years working on transformational technology and its responsible application in markets, research and society. What I see in the QScreen AI platform is an innovative use of technology in an environment that has broad applicability. Reading physiological signals in real time is a real key for human safety, early detection and effective care in so many challenging human environments. Whatever business we are in, care and management of human interactions is so important."

Dr. Rahul Kushwah, chief operating officer of QScreen AI, stated:

"Lt. Gen. Groen helped lead the Department of Defense's adoption of artificial intelligence across some of the most demanding operational environments in the world. He has evaluated AI platforms at the highest institutional levels and his decision to join QScreen following a live demonstration of the platform is a significant milestone for the company. Combined with Beto Vargas's relationships across North American rail and logistics, we believe QScreen is continuing to build the strategic relationships needed to advance commercialization across defence, correctional health, transportation and institutional safety markets."

About QScreen AI Inc.

QScreen AI Inc. is a health technology company building a proprietary artificial intelligence engine with quantum inspired computing and advanced physiological sensing to clinical and occupational health assessments across correctional facilities, addiction medicine rehabilitation and industrial work force screening in multiple jurisdictions.

We seek Safe Harbor.